65,437 trials
Huntington's Disease
Primary: Change From Baseline in the Total Motor Score (TMS) Assessment of the Unified Huntington Disease Rating Scale (UHDRS) After 26 Weeks of Treatment. — 0.4; -0.8; -1.4…
Prostate Cancer
Primary: Progression Free Survival (PFS) — 5.7; 5.6 months — p=0.2176
Hypophosphatasia
Primary: Long-term Tolerability of Subcutaneous (SC) Asfotase Alfa — 10 Participants
Hypoglycemia
Primary: Change From Baseline in Cardiovascular Autonomic Function — -16.00; -16.59 ms/mmHg
Chronic Heart Failure
Primary: Hospitalizations — .55; .78 participant mean hospitalizations/90 day
Hyperhidrosis
Primary: Mean Plasma Concentration After Repeat Dosing of Umeclidinium — 33.09; 29.86; 41.22; 42.72 picogram per millilitre (pg/ml)
Coronary Artery Disease
Primary: AUC of FFRct Versus Coronary CTA for Demonstration of Ischemia (≤0.80) on a Per-patient Basis — .90; .81 probablility
Diffuse Large B Cell Lymphoma
Primary: Number of Participants With Adverse Events, Injection Site Reactions, and Concomitant Medications — 4; 1; 3 Participants
HIV
Primary: Number of Participants With Sustained Virologic Response — 33 Participants
Oropharyngeal Dysphagia
Primary: Change in Swallow Frequency 30 Hz — 0.512 Change in swallows/min — p=0.218
Diabetes Mellitus
Primary: Mean Plasma Blood Glucose Achieved by the Bionic Pancreas (mg/dl) — 132; 146; 162; 175 mg/dl
Atrial Fibrillation
Primary: Incidence of Major Bleeding Events (MBEs), as Defined by the International Society on Thrombosis and Haemostasis (ISTH) — 1.6; 6.9 percentage of participants — p=0.0009
Attention Deficit Hyperactivity Disorder
Primary: Adult ADHD Investigator Symptom Rating Scale (AISRS) — -22.9; -20.8 units on a scale
Bladder Cancer · Urothelial Carcinoma
Primary: Overall Survival — 6.4; 5.9 months
Congenital Heart Disease · Single Ventricle
Primary: Change in Peak VO2 Between Baseline and Post-inspiratory Muscle Training Measurements. — 24.0 ml/kg/min — p=0.1673